NZ733296B2 - Rnai induced huntingtin gene suppression - Google Patents
Rnai induced huntingtin gene suppression Download PDFInfo
- Publication number
- NZ733296B2 NZ733296B2 NZ733296A NZ73329615A NZ733296B2 NZ 733296 B2 NZ733296 B2 NZ 733296B2 NZ 733296 A NZ733296 A NZ 733296A NZ 73329615 A NZ73329615 A NZ 73329615A NZ 733296 B2 NZ733296 B2 NZ 733296B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- sequence
- rna
- seq
- double stranded
- stranded rna
- Prior art date
Links
- 230000002987 rna-interference Effects 0.000 title description 31
- 230000001629 suppression Effects 0.000 title description 6
- 229920001850 Nucleic acid sequence Polymers 0.000 claims abstract description 242
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims abstract description 148
- 108020004461 Double-Stranded RNA Proteins 0.000 claims abstract description 124
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 124
- 239000002773 nucleotide Substances 0.000 claims abstract description 123
- 230000000295 complement Effects 0.000 claims abstract description 59
- 239000002679 microRNA Substances 0.000 claims description 135
- 230000014509 gene expression Effects 0.000 claims description 78
- 108020004459 Small Interfering RNA Proteins 0.000 claims description 56
- 239000004055 small Interfering RNA Substances 0.000 claims description 53
- 201000001971 Huntington's disease Diseases 0.000 claims description 37
- 108091007167 primary miRNA Proteins 0.000 claims description 36
- 229920001891 Small hairpin RNA Polymers 0.000 claims description 22
- 210000004027 cells Anatomy 0.000 claims description 20
- 238000001415 gene therapy Methods 0.000 claims description 18
- 210000004556 Brain Anatomy 0.000 claims description 15
- 229920000348 MiR-155 Polymers 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 12
- 210000001577 Neostriatum Anatomy 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims 1
- 230000025458 RNA interference Effects 0.000 abstract description 32
- 230000001939 inductive effect Effects 0.000 abstract description 12
- 238000010171 animal model Methods 0.000 abstract description 4
- 230000016273 neuron death Effects 0.000 abstract description 4
- 229920001239 microRNA Polymers 0.000 description 44
- 108020004388 MicroRNAs Proteins 0.000 description 41
- 229920001985 Small interfering RNA Polymers 0.000 description 34
- 230000000875 corresponding Effects 0.000 description 30
- 238000003197 gene knockdown Methods 0.000 description 26
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 13
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000005089 Luciferase Substances 0.000 description 11
- 108060001084 Luciferase family Proteins 0.000 description 11
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 229920002106 messenger RNA Polymers 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 108020004999 Messenger RNA Proteins 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 102000016252 Huntingtin Human genes 0.000 description 5
- 108050004784 Huntingtin family Proteins 0.000 description 5
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 210000002569 neurons Anatomy 0.000 description 5
- 108020004394 Complementary RNA Proteins 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000003612 virological Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 101700016569 AIF1 Proteins 0.000 description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 229920002459 Intron Polymers 0.000 description 3
- 101710029649 MDV043 Proteins 0.000 description 3
- 101700054624 RF1 Proteins 0.000 description 3
- 241000242739 Renilla Species 0.000 description 3
- 229940035893 Uracil Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 108060002324 polC Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960000643 Adenine Drugs 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 210000000234 Capsid Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940104302 Cytosine Drugs 0.000 description 2
- 101700070897 ENO2 Proteins 0.000 description 2
- 102100003738 ENO2 Human genes 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000970 Repeated sequence (DNA) Polymers 0.000 description 2
- 241000519995 Stachys sylvatica Species 0.000 description 2
- 229920000401 Three prime untranslated region Polymers 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- TXWCDJYEKHLJSO-MYINAIGISA-N 1-[(2S,4S,5R)-2-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@@]1(F)N1C(=O)NC(=O)C=C1 TXWCDJYEKHLJSO-MYINAIGISA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101700027746 AGO2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004040 Capsid Proteins Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100008005 GPR180 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 101700006422 Rep40 Proteins 0.000 description 1
- 101700003689 Rep52 Proteins 0.000 description 1
- 101700006973 Rep68 Proteins 0.000 description 1
- 101700082620 Rep78 Proteins 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- 229920000972 Sense strand Polymers 0.000 description 1
- 102000017299 Synapsin-1 Human genes 0.000 description 1
- 108050005241 Synapsin-1 Proteins 0.000 description 1
- 210000001103 Thalamus Anatomy 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000000185 intracerebroventricular Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010946 mechanistic model Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 108091007165 microRNA precursor Proteins 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000002981 neuropathic Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing Effects 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
Abstract
The present invention provides for a double stranded RNA comprising a first RNA sequence and a second RNA sequence wherein the first and second RNA sequence are substantially complementary, wherein the first RNA sequence has a sequence length of at least 19 nucleotides and is substantially complementary to SEQ ID NO. 1. Said double stranded RNA is for use in inducing RNAi against Huntingtin exon 1 sequences. The double stranded RNA of to the invention was capable of reducing neuronal cell death and huntingtin aggregates in an animal model. tary to SEQ ID NO. 1. Said double stranded RNA is for use in inducing RNAi against Huntingtin exon 1 sequences. The double stranded RNA of to the invention was capable of reducing neuronal cell death and huntingtin aggregates in an animal model.
Description
Title RNAi induced Huntingtin gene suppression
Background
The huntingtin gene, also referred to as the HTT or HD (Huntington’s disease) gene, encodes
for the huntingtin protein. The huntingtin gene is a large gene of about 13.5kb (huntingtin
protein is about 350 kDa). Huntington’s disease is a genetic neurodegenerative disorder
caused by a genetic mutation in the huntingtin gene. The genetic mutation involves a DNA
segment of the huntingtin gene known as the CAG trinucleotide repeat. Normally, the CAG
segment in the huntingtin gene of humans is repeated multiple times, i.e. about 10-35 times.
People that develop Huntington’s disease have an expansion of the number of CAG repeats
in at least one allele. An affected person usually inherits the mutated allele from one affected
parent. In rare cases, an individual with Huntington’s disease does not have a parent with the
disorder (sporadic HD). People with 36 to 39 CAG repeats may develop signs and symptoms
of Huntington disease, while people with 40 or more repeats almost always develop the
disorder. The increase in the size of the CAG repeat leads to the production of an elongated
(mutated) huntingtin protein. This protein is processed in the cell into smaller fragments that
are cytotoxic and that accumulate and aggregate in neurons. This results in the disruption of
normal function and eventual death of neurons. This is the process that occurs in the brain
which underlies the signs and symptoms of Huntington’s disease.
RNA interference (RNAi) is a naturally occurring mechanism that involves sequence
specific down regulation of mRNA. The down regulation of mRNA results in a reduction of the
amount of protein that is expressed. RNA interference is triggered by double stranded RNA.
One of the strands of the double stranded RNA is substantially or completely complementary
to its target, the mRNA. This strand is termed the guide strand. The mechanism of RNA
interference involves the incorporation of the guide strand in the RNA-induced silencing
complex (RISC). This complex is a multiple turnover complex that via complementary base
paring binds to its target mRNA. Once bound to its target mRNA it can either cleave the
mRNA or reduce translation efficiency. RNA interference has since its discovery been widely
used to knock down specific target genes. The triggers for inducing RNA interference that
have been employed involve the use of siRNAs or shRNAs. In addition, molecules that can
naturally trigger RNAi, the so called miRNAs, have been used to make artificial miRNAs that
mimic their naturally occurring counterparts. These strategies have in common that they
provide for substantially double stranded RNA molecules that are designed to target a gene
of choice. RNAi based therapeutic approaches that utilise the sequence specific modality of
RNAi are under development and several are currently in clinical trials (see i.a. Davidson and
McCray, Nature Reviews - Genetics, 2011; Vol.12; 329-340).
18023480_1 (GHMatters) P43075NZ00
As Huntington’s disease involves the expression of a mutant huntingtin protein, the
accumulation thereof leading to disease, RNA interference provides for an opportunity to treat
the disease as it can reduce expression of the huntingtin gene. The paradigm underlying this
approach involves a reduction of the mutant Htt protein to thereby reduce the toxic effects
resulting from the mutant Htt protein to achieve a reduction and/or delay of Huntington’s
disease symptoms, or even to prevent Huntington’s disease symptoms altogether. Targeting
huntingtin gene suppression has been hypothesized in the prior art, including the listing of
about two thousand of hypothetical siRNA target sequences (WO2005105995). Strategies to
reduce huntingtin gene expression are known in the art and involve the specific targeting of
mutant huntingtin genes (e.g. US20090186410, US20110172291). Alternatively, RNA
interference has also been employed to target both mutant and non-mutant genes (e.g.
Rodriguez-Lebron et al., 2005, Mol Ther. Vol 12 No.4: 618-633; Franich et al., 2008, Mol
Ther, Vol. 16 No.5; 947-956; Drouet et al., 2009, Annals of Neurology; Vol.65 No.3; 276-285
and McBride et al. Mol Ther. 2011 Dec;19(12):2152-62; US20080015158, WO2008134646).
In the latter case, knockdown of the wild type Huntingtin protein was shown not to have any
apparent detrimental effects.
Summary of the invention
A first aspect provides a double stranded RNA comprising a first RNA sequence and a
second RNA sequence wherein the first and second RNA sequence are substantially
complementary, wherein the first RNA sequence has a sequence length of at least 19
nucleotides and is complementary to SEQ ID NO. 1, wherein the first sequence is selected
from the group consisting of SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, and
SEQ ID NO.7, and wherein said double stranded RNA is capable of reducing huntingtin gene
expression.
A second aspect provides a DNA sequence encoding a double stranded RNA
according to the first aspect.
A third aspect provides an expression cassette encoding a double stranded RNA
according to the first aspect.
A fourth aspect provides a gene therapy vector comprising an expression cassette
according to the third aspect.
A fifth aspect provides an isolated or non-human host cell comprising a DNA
sequence according to the second aspect or an expression cassette according to the third
aspect.
A sixth aspect provides use of a double stranded RNA according to the first aspect, a
DNA sequence according to the second aspect, an expression cassette according to the third
18023480_1 (GHMatters) P43075NZ00
aspect, or a gene therapy vector according to the fourth aspect in the manufacture of a
medicament for treating Huntington’s disease in a subject or a subject genetically
predisposed for Huntington’s disease who does not yet show symptoms of Huntington’s
disease.
The present disclosure relates to a double stranded RNA comprising a first RNA
sequence and a second RNA sequence wherein the first and second RNA sequence are
substantially complementary, wherein the first RNA sequence has a sequence length of at
least 19 nucleotides and is substantially complementary to SEQ ID NO. 1. A large number of
target sequences were tested for effective knockdown of the huntingtin gene. The selected
double stranded RNA of the current invention was found to be effective in reducing huntingtin
gene expression. Said double stranded RNA when provided in a cell, either directly via
transfection or indirectly via delivery of DNA (e.g. transfection) or via vector-mediated
expression upon which the said double stranded RNA can be expressed, is capable of
reducing expression of both a mutated huntingtin gene and a normal huntingtin gene.
Furthermore, it was shown that the double stranded RNA of the disclosure was capable of
reducing target gene expression when provided either as an siRNA or in a miRNA scaffold.
When tested in an animal model, it was shown that a double stranded RNA according to the
invention was capable of reducing neuronal cell death and huntingtin aggregates. The double
stranded RNA as provided in the current disclosure relates to an improvement as compared
to double stranded RNAs in the art targeting the huntingtin gene, or relates to at least an
alternative thereto.
The double stranded RNA according to the disclosure can be provided as an siRNA, a
shRNA, a pre-miRNA or pri-miRNA. Such double stranded RNAs may be delivered to the
target cells directly, e.g. via cellular uptake using e.g. transfection methods. Preferably, said
delivery is achieved using a gene therapy vector, wherein an expression cassette for the
siRNA, shRNA, pre-miRNA or pri-miRNA is included in a vector. This way, cells can be
provided with a constant supply of double stranded RNA to achieve durable huntingtin gene
suppression without requiring repeated administration. Preferably, the viral vector of choice is
AAV5. The current disclosure relates to the medical use of a double stranded RNA according
to the disclosure, such as the treatment or Huntington’s disease, wherein such medical use
may also comprise an expression cassette or a viral vector, such as AAV5, capable of
expressing the said double stranded RNA of the disclosure.
Figures
Fig.1 Human huntingtin (HTT) gene and target sequences. (A) Schematic of the
human HTT gene (L27350.1) with CAG expansions (black) and target sequences for miH1-
18023480_1 (GHMatters) P43075NZ00
H21 (light grey) (B) Exon 1 RNA sequence of the HTT gene (SEQ ID NO.2). The CAG repeat
sequence is from nts. 367-429. (C) Schematic of target sequences tested for exon 1 (H1,
185-205; H2, 186-206; H3, 189-209; H4, 191-211; H5, 194-214; H6, 196-216; H7, 250-270;
H8, 261-281, H9, 310-330; H10, 311-331, H11, 339-359, H12, 345-365, H13, 454-474; H14,
459-479; H15, 477-497; H16, 486-506; H17, 492-512; H18, 498-518; H19, 549-569; H20,
557-577; H21, 558-578, H1-H21 corresponding to SEQ ID NOs.23-43). The sequences
depicted are DNA sequences. The numbers refer to the corresponding RNA nucleotide
sequences in SEQ ID NO.2. The corresponding RNA target sequences of SEQ ID NO.2 have
the sequence as listed in C) except that wherein the DNA encodes a “ t “ the RNA encodes a
“ U “.
Fig.2. Examples of double stranded RNAs and expression cassettes. (A) Examples of
pri-/pre-miRNA scaffold for miH12 pre-miH12-155 (SEQ ID NO.44) and pre-miH12-451
scaffold (SEQ ID NO.45) with miH12 guide (grey) indicated. (B) Schematic outlining of the
double stranded RNAs in accordance with the invention and how they can be processed by
the RNAi machinery. A double stranded RNA may be a short hairpin RNA (1) or an extended
siRNA (2). The hairpin RNA or extended siRNA has the first RNA sequence at the proximal
end, as indicated (indicated with 1 and brackets). A short hairpin RNA or an extended siRNA
can be processed by the RNAi machinery in the cell to produce an siRNA (3), which can also
be a double stranded RNA according to the invention, of which one strand comprising the first
RNA sequence can be incorporated into the RISC complex (4). A double stranded RNA can
be comprised in a pri-miRNA sequence (5) or a pre-miRNA sequence (6). The pri-miRNA can
be processed by the RNAi machinery to produce a pre-miRNA and subsequently a mature
miRNA duplex (7), of which one strand comprising the first RNA sequence can be
incorporated into the RISC complex (4). The position of the first RNA sequence in the pre-
miRNA, pri-miRNA and miRNA duplex is indicated 1 and brackets. (C) DNA sequence of the
pVD-CMV-miH12-155 expression cassette (CMV promoter (1-588), intervening sequence,
Green Fluorescent Protein GFP sequence (713-1432), 5’ pri-miRNA flank (1433-1514), 5’
pre-miRNA, Guide strand (first RNA sequence) (1520-1540), loop sequence, Passenger
strand (second RNA sequence) (1560-1578), 3’ pre-miRNA) 3’ pri-miRNA flank (1584-1704),
HSV TKpolyA signal (1705-1976); (D) DNA sequence of the pVD-CAG-miH12-451 (CAG
promoter (43-1715), 5’ pri-miRNA flank (1716-2017), 5’ pre-miRNA, Guide strand (first RNA
sequence) (2034-2054), second RNA sequence &, 3’ pre-miRNA, 3’ pri-miRNA flank (2090-
2320), hGH polyA signal (2321-2417) and (E) DNA sequence of the pVD-PGK-miH12-451
expression cassette (PGK promoter (23-277), 5’ pri-miRNA flank (278-794), 5’ pre-miRNA,
Guide strand (first RNA sequence) (811-831), second RNA sequence &, 3’ pre-miRNA, 3’ pri-
miRNA flank (867-1097), hGH polyA signal (1098-1194). (F) pri-miH12-155 sequence that is
18023480_1 (GHMatters) P43075NZ00
encoded by pVD-CMV-miH12-155. (G) pri-miH12-451 sequence that is encoded by pVD-
CAG-miH12-451. (G) pri-miH12-451 sequence that is encoded by pVD-PGK-miH12-451. For
figure (E), (F) and (G), the font type is the same as used above for the corresponding DNA.
Promoter sequences are bold, Green Fluorescent protein sequence is in italics underlined
(only C), pri-miRNA sequences have a normal font type, guide strand (first RNA sequence) is
in bold italics and the passenger strand or second RNA sequence is in italics, pre-miRNA
sequences are underlined and the polyA signal is bold underlined.
Fig. 3. In vitro knockdown efficacy of miH1-21. (A) Total HTT knockdown by targeting
exon 1. LucHTT was co-transfected in Hek293T cells with miH1-miH21. Renilla and Firefly
luciferase fluorescence was measured 48h post-transfection. miScr (ctrl) was used as a
negative control and was set at 100%. miH12 showed strongest knockdown efficiency.
(B) LucHTT knockdown was by synthetic siH12 with19-23 nucleotides of length.
Fig. 4. In vitro knockdown efficacy of miH12-451 with different promoters. (A) LucHTT
reporter has been co-transfected with CAG-miH12 or PGK-miH12 variants and knockdown
efficacy was determined as described above for Fig.3. (B) Passenger (*) strand activity of
miH12-451* expressed from the CAG or PGK promoters was measured on specific LucHTT*
reporters. No passenger strand activity was detected.
Fig. 5. In vivo efficacy of AAV5-delivered miH12. (A) Experimental set up. Mice were
co-injected with AAV5-Luc73QHTT and AAV5-CMV-miScr-155 or AAV5-CMV-miH12-155 in
1:5 ratio. Measurement points are indicated with arrows; (B) AAV5-Luc73QHTT knockdown in
animals 6 weeks p.i. was measured by IVIS; (C) AAV5-Luc73QHTT knockdown trend by
AAV5-miH12 up to 6 weeks p.i.
Fig. 6. Human HTT knockdown proof of concept in rat HD mechanistic model. (A)
Experimental set up; (B) brain histology showing less neurodegeneration (DARP32) and less
mutant Htt (EM48) aggregates in the AAV5-CMV-miH12-155 group; (C) GFP brain histology;
(D) Iba1 immune activation marker brain histology.
Fig. 7. Human HTT knockdown in the humanized Hu97/18 HD mouse model. (A)
Transduction efficiency in murine brain upon slow intrastriatal injection, convection enhanced
diffusion (CED) intrastriatal injection or intracerebral ventricular (ICV) injection of AAV5-CMV-
miH12-155. GFP fluorescence was viewed 5 weeks post injection. (B) Western blot
measuring human HTT knockdown in murine brain upon AAV5-miHTT delivery. (C) HTT
western blot quantification.
Fig. 8. Comparison of selected H12 target with prior art target sequences. LucHTT
was co-transfected in Hek293T cells with the indicated siRNAs (A) and miRNA constructs (B
and C). Renilla and Firefly luciferase fluorescence was measured 48h post-transfection.
miH12 and siH12 showed strongest knockdown efficiency.
18023480_1 (GHMatters) P43075NZ00
Detailed description
The present invention provides for a double stranded RNA comprising a first RNA
sequence and a second RNA sequence wherein the first and second RNA sequence are
substantially complementary, wherein the first RNA sequence has a sequence length of at
least 19 nucleotides and is substantially complementary to SEQ ID NO. 1.
SEQ ID NO.1 (5’-CUUCGAGUCCCUCAAGUCCUU-3’) corresponds to a target
sequence of the huntingtin gene of exon 1 (SEQ ID NO. 2). Exon 1, as depicted in Fig. 1B
has 21 repeat CAG sequences from nt. 367-429. The exon 1 sequence as depicted in fig. 1B
corresponds to a normal huntingtin gene that is not associated with disease. Corresponding
mutant huntingtin genes associated with Huntington’s disease comprise much more than 21
CAG repeat sequences. As said, with 36 to 39 CAG repeats one may develop signs and
symptoms of Huntington’s disease, while with 40 or more repeats one almost always develop
the disorder. The target sequence SEQ ID NO.1 is comprised in substantially all exon 1
sequences, irrespective of the number of CAG repeats.
SEQ ID NO. 1 corresponds to nucleotide nrs. 345-365 of SEQ ID NO.2. 18 different
target sequences in exon 1 were tested for targeting using double stranded RNAs that were
designed to induce a sequence specific inhibition of SEQ ID NO.2. (see figure 1 and figure
3A) and it was found that in particular targeting this sequence from exon 1 was useful in
reducing huntingtin gene expression. siRNAs varying in length, i.e. consisting of 19, 20, 21,
22, and 23 consecutive basepairs with 2 nucleotide overhangs in addition were found to be
effective against this sequence, as well as two separate miRNA scaffolds carrying a 21
nucleotide sequence complementary to SEQ ID NO.1 at the guide sequence position (see
figures 3A, 3B and 4). Hence, the first RNA sequence that is substantially complementary to
the huntingtin target sequence SEQ ID NO.1 has a sequence length of at least 19
nucleotides.
The first RNA sequence according to the invention is comprised in the guide strand of
the double stranded RNA, also referred to as antisense strand as it is complementary (“anti”)
to the sense target sequence. The second RNA sequence is comprised in the passenger
strand, also referred to as “sense strand” as it may have substantial sequence identity with or
be identical with the target sequence. The first and second RNA sequences are comprised in
a double stranded RNA and are substantially complementary. The said double stranded RNA
according to the invention is to induce RNA interference to thereby reduce both huntingtin
mutant and wild type gene expression. Hence, it is understood that substantially
complementary means that it is not required to have all the nucleotides of the first and second
RNA sequences base paired, i.e. to be fully complementary, or all the nucleotides of the first
18023480_1 (GHMatters) P43075NZ00
RNA sequence and SEQ ID NO.1 base paired. As long as the double stranded RNA is
capable of inducing RNA interference to thereby sequence specifically target a sequence
comprising SEQ ID NO.1, such substantial complementarity is contemplated in the invention.
Hence, in one embodiment the double stranded RNA according to the invention
comprising a first RNA sequence and a second RNA sequence wherein the first and second
RNA sequence are substantially complementary, and wherein the first RNA sequence has a
sequence length of at least 19 nucleotides and is substantially complementary to SEQ ID NO.
1, is capable of inducing RNA interference to sequence specifically reduce expression of an
RNA transcript comprising SEQ ID NO.1. In a further embodiment, said induction of RNA
interference to reduce expression of an RNA transcript comprising SEQ ID NO.1 means that
it is to reduce human Huntingtin gene expression.
One can easily determine whether this is the case by using standard luciferase
reporter assays and appropriate controls such as described in the examples and as known in
the art (Zhuang et al. 2006 Methods Mol Biol. 2006;342:181-7). For example, a luciferase
reporter comprising SEQ ID No.1 can be used to show that the double stranded RNA
according to the invention is capable of sequence specific knock down. Furthermore, as
shown in the example section, Huntingtin expression can be determined with specific
antibodies to determine the amount of expression in a western blot analysis, as can northern
blot analysis detecting the amount of RNA transcript.
Hence, the double stranded RNA according to the invention is for use in inducing RNA
interference. The double stranded RNA according to the invention is for use in reducing
expression of transcripts comprising SEQ ID NO.1, such as for example SEQ ID NO.2 or the
like with varying number of CAG repeats.
As said, the double stranded RNA is capable of inducing RNA interference. Double
stranded RNA structures are well known in the art that are suitable for inducing RNAi. For
example, a small interfering RNA (siRNA) comprises two separate RNA strands, one strand
comprising the first RNA sequence and the other strand comprising the second RNA
sequence. An siRNA design that is often used involves 19 consecutive base pairs with 3’ two-
nucleotide overhangs (see figure 2A). This design is based on observed Dicer processing of
larger double stranded RNAs that results in siRNAs having these features. The 3’-overhang
may be comprised in the first RNA sequence. The 3’-overhang may be in addition to the first
RNA sequence. The length of the two strands of which an siRNA is composed may be 19, 20,
21, 22, 23, 24, 25, 26 or 27 nucleotides or more. Each of the two strands comprises the first
and second RNA sequence. The strand comprising the first RNA sequence may also consist
thereof. The strand comprising the first RNA sequence may also consist of the first RNA
sequence and the overhang sequence.
18023480_1 (GHMatters) P43075NZ00
siRNAs may also serve as Dicer substrates. For example, a Dicer substrate may be a
27-mer consisting of two strands of RNA that have 27 consecutive base pairs. The first RNA
sequence is positioned at the 3’-end of the 27-mer duplex. At the 3’-end, like the with siRNAs,
is a two nucleotide overhang. The 3’-overhang may be comprised in the first RNA sequence.
The 3’-overhang may be in addition to the first RNA sequence. 5’ from the first RNA
sequence, additional sequences may be included that are either complementary to the target
sequence adjacent to SEQ ID NO.1 or not. The other end of the siRNA dicer substrate is
blunt ended. This dicer substrate design results in a preference in processing by Dicer such
that an siRNA is formed like the siRNA design as described above, having 19 consecutive
base pairs and 2 nucleotide overhangs at both 3’-ends. In any case, siRNAs, or the like, are
composed of two separate RNA strands (Fire et al. 1998, Nature. 1998 Feb
19;391(6669):806-11) each RNA strand comprising or consisting of the first and second RNA
sequence according to the invention.
The double stranded RNA according to the invention does not require both first and
second RNA sequences to be comprised in two separate strands. The first and second RNA
sequences can also be comprised in a single strand of RNA, such as e.g. an shRNA. A
shRNA may comprise from 5’ - second RNA sequence – loop sequence – first RNA sequence
– optional 2 nt overhang sequence - 3’. Alternatively, a shRNA may comprise from 5’ - first
RNA sequence – loop sequence – second RNA sequence – optional 2 nt overhang sequence
- 3’. Such an RNA molecule forms intramolecular base pairs via the substantially
complementary first and second RNA sequence. Suitable loop sequences are well known in
the art (i.a. as shown in Dallas et al. 2012 Nucleic Acids Res. 2012 Oct;40(18):9255-71and
Schopman et al., Antiviral Res. 2010 May;86(2):204-11).
The loop sequence may also be a stem-loop sequence, whereby the double
stranded region of the shRNA is extended. Without being bound by theory, like the siRNA
dicer substrate as described above, a shRNA is usually processed by Dicer to obtain e.g. an
siRNA having an siRNA design such as described above, having e.g. 19 consecutive base
pairs and 2 nucleotide overhangs at both 3’-ends. In case the double stranded RNA is to be
processed by Dicer, it is preferred to have the first and second RNA sequence at the end of
A double stranded RNA according to the invention may also be incorporated in a pre-
miRNA or pri-mi-RNA scaffold. Micro RNAs, i.e. miRNA, are guide strands that originate from
double stranded RNA molecules that are expressed e.g. in mammalian cells. A miRNA is
processed from a pre-miRNA precursor molecule, similar to the processing of a shRNA or an
extended siRNA as described above, by the RNAi machinery and incorporated in an activated
RNA-induced silencing complex (RISC) (Tijsterman M, Plasterk RH. Dicers at RISC; the
mechanism of RNAi. Cell. 2004 Apr 2;117(1):1-3). Without being bound by theory, a pre-
18023480_1 (GHMatters) P43075NZ00
miRNA is a hairpin molecule that can be part of a larger RNA molecule (pri-miRNA), e.g.
comprised in an intron, which is first processed by Drosha to form a pre-miRNA hairpin
molecule. The pre-miRNA molecule is a shRNA-like molecule that can subsequently be
processed by dicer to result in an siRNA-like double stranded duplex. The miRNA, i.e. the
guide strand, that is part of the double stranded RNA duplex is subsequently incorporated in
RISC. An RNA molecule such as present in nature, i.e. a pri-miRNA, a pre-miRNA or a
miRNA duplex, may be used as a scaffold for producing an artificial miRNA that specifically
targets a gene of choice. Based on the predicted RNA structure, e.g. as predicted using e.g.
m-fold software, the natural miRNA sequence as it is present in the RNA structure (i.e.
duplex, pre-miRNA or pri-miRNA), and the sequence present in the structure that is
complementary therewith are removed and replaced with a first RNA sequence and a second
RNA sequence according to the invention. The first RNA sequence and the second RNA
sequence may be selected such that the RNA structures that are formed, i.e. pre-miRNA, pri-
miRNA and/or miRNA duplex, resemble the corresponding predicted original sequences.
pre-miRNA, pri-miRNA and miRNA duplexes (that consist of two separate RNA strands that
are hybridized via complementary base pairing), as found in nature often are not fully base
paired, i.e. not all nucleotides that correspond with the first and second strand as defined
above are base paired, and the first and second strand are often not of the same length. How
to use miRNA precursor molecules as scaffolds for any selected target sequence and
substantially complementary first RNA sequence is described e.g. in Liu YP Nucleic Acids
Res. 2008 May;36(9):2811-24.
In any case, as is clear from the above, the double stranded RNA comprising the first
and second RNA sequence can comprise additional nucleotides and/or nucleotide
sequences. The double stranded RNA may be comprised in a single RNA sequence or
comprised in two separate RNA strands. Without being bound by theory, whatever design is
used for the double stranded RNA, it is designed such that an antisense sequence
comprising the first RNA sequence of the invention can be processed by the RNAi machiney
such that it can be incorporated in the RISC complex to have its action. The said sequence
comprising or consisting of the first RNA sequence of the invention being capable of
sequence specifically targeting SEQ ID NO.1. Hence, as long as the double stranded RNA is
capable of inducing RNAi, such a double stranded RNA is contemplated in the invention.
Hence, in one embodiment, the double stranded RNA according to the invention is comprised
in a pre-miRNA scaffold, a pri-miRNA scaffold, a shRNA, or an siRNA.
The term complementary is defined herein as nucleotides of a nucleic acid sequence
that can bind to another nucleic acid sequence through hydrogen bonds, i.e. nucleotides that
are capable of base pairing. Ribonucleotides, the building blocks of RNA are composed of
18023480_1 (GHMatters) P43075NZ00
monomers (nucleotides) containing a sugar, phosphate and a base that is either a purine
(guanine, adenine) or pyrimidine (uracil, cytosine). Complementary RNA strands form double
stranded RNA. A double stranded RNA may be formed from two separate complementary
RNA strands or the two complementary RNA strands may be comprised in one RNA strand.
In complementary RNA strands, the nucleotides cytosine and guanine (C and G) can form a
base pair, guanine and uracil (G and U), and uracil and adenine (U and A). The term
substantial complementarity means that is not required to have the first and second RNA
sequence to be fully complementary, or to have the first RNA sequence and SEQ ID NO.1 to
be fully complementary. For example, the first and second nucleotides as shown in figure 2A
are substantially complementary and not fully complementary.
In one embodiment, the substantial complementarity between the first RNA sequence
and SEQ ID NO.1 consists of having no mismatches, one mismatched nucleotide, or two
mismatched nucleotides. It is understood that one mismatched nucleotide means that over
the entire length of the first RNA sequence that base pairs with SEQ ID NO.1 one nucleotide
does not base pair with SEQ ID NO.1. Having no mismatches means that all nucleotides
base pair with SEQ ID NO.1, and having 2 mismatches means two nucleotides do not base
pair with SEQ ID NO.1. The first RNA sequence may also be longer than 21 nucleotides, in
this scenario, the substantial complementarity is determined over the entire length of SEQ ID
NO.1. This means that SEQ ID NO.1 in this embodiment has either no, one or two
mismatches over its entire length when base paired with the first RNA sequence. For
example, as shown in figure 3B and the examples, siRNAs having a first nucleotide sequence
length of 22 and 23 nucleotides were tested. These first nucleotide sequences had no
mismatches and were fully complementary to SEQ ID NO.1. Having a few mismatches
between the first nucleotide sequence and SEQ ID NO.1 may be allowed according to the
invention, as long as the double stranded RNA according to the invention is capable of
reducing expression of transcripts comprising SEQ ID NO.1, such as a luciferase reporter or
e.g. a transcript comprising SEQ ID NO.1. In this embodiment, substantial complementarity
between the first RNA sequence and SEQ ID NO.1 consists of having no, one or two
mismatches over the entire length of either the first RNA sequence or SEQ ID NO.1,
whichever is the shortest.
In one embodiment the first RNA sequence and SEQ ID NO.1 have at least 15, 16,
17, 18, or 19 nucleotides that base pair. Preferably the first RNA sequence and SEQ ID NO. 1
are substantially complementary, said complementarity comprising at least 19 base pairs. In
another embodiment, the first RNA sequence has at least 8, 9, 10, 11, 12, 13 or 14
consecutive nucleotides that base pair with consecutive nucleotides of SEQ ID NO.1. In
another embodiment, the first RNA sequence has at least 19 consecutive nucleotides that
18023480_1 (GHMatters) P43075NZ00
base pair with consecutive nucleotides of SEQ ID NO.1. In another embodiment the first RNA
sequence comprises at least 19 consecutive nucleotides that base pair with 19 consecutive
nucleotides of SEQ ID NO.1. In still another embodiment, the first RNA sequence has at least
17 nucleotides that base pair with SEQ ID NO.1 and has at least 15 consecutive nucleotides
that base pair with consecutive nucleotides of SEQ ID NO.1. The sequence length of the first
nucleotide is at most 21, 22, 23, 24, 25, 26, or 27 nucleotides.
As said, a mismatch according to the invention means that a nucleotide of the first
RNA sequence does not base pair with SEQ ID NO.1. Nucleotides that do not base pair are A
and C, C and U, or A and G. A mismatch may also result from a deletion of a nucleotide, or
an insertion of a nucleotide. When the mismatch is a deletion in the first RNA sequence, this
means that a nucleotide of SEQ ID NO.1 is not base paired with the first RNA sequence when
compared with the entire length of the first RNA sequence. Nucleotides that can base pair are
A-U, G-C and G-U. A G-U base pair is also referred to as a G-U wobble, or wobble base pair.
In one embodiment the number of G-U base pairs between the first RNA sequence and SEQ
ID NO.1 is 0, 1 or 2. In one embodiment, there are no mismatches between the first RNA
sequence and SEQ ID NO.1 and a G-U base pair or G-U pairs are allowed. Preferably, there
may be no G-U base pairs between the first RNA sequence and SEQ ID NO.1, or the first
RNA sequence and SEQ ID NO.1 only have base pairs that are A-U or G-C. Preferably, there
are no G-U base pairs and no mismatches between the first RNA sequence and SEQ ID
NO.1. Hence, the first RNA sequence of the double stranded RNA according to invention
preferably is fully complementary to SEQ ID NO.1, said complementarity consisting of G-C
and A-U base pairs.
It may be not required to have full complementarity (i.e. full base pairing (no
mismatches) and no G-U base pairs) between the first nucleotide sequence and SEQ ID
NO.1 as such a first nucleotide sequence can still allow for sufficient suppression of gene
expression. Also, having not full complementarity may be contemplated for example to avoid
or reduce off-target sequence specific gene suppression while maintaining sequence specific
inhibition of transcripts comprising SEQ ID NO.1. However, it may be preferred to have full
complementarity as it may result in more potent inhibition. Without being bound by theory,
having full complementarity between the first RNA sequence and SEQ ID NO.1 may allow for
the activated RISC complex comprising the said first RNA sequence to cleave its target
sequence, whereas having mismatches may only allow inhibition of translation, the latter
resulting in less potent inhibition.
In one embodiment, the first RNA sequence has a sequence length of at least 19
nucleotides, preferably 20 nucleotides, more preferably of at least 21 nucleotides. The
18023480_1 (GHMatters) P43075NZ00
sequence length can also be at least 22 nucleotides, or at least 23 nucleotides. The first RNA
sequence according to the invention may be selected from SEQ ID NOs. 3-7.
SEQ ID First RNA sequence length
3 5’-AAGGACUUGAGGGACUCGA-3’ 19
4 5’-AAGGACUUGAGGGACUCGAA-3’ 20
5’-AAGGACUUGAGGGACUCGAAG-3’ 21
6 5’-AAGGACUUGAGGGACUCGAAGG-3’ 22
7 5’-AAGGACUUGAGGGACUCGAAGGC-3’ 23
Table 1: First RNA sequences.
The first RNA sequences of table 1 have been shown to specifically inhibit transcripts
comprising SEQ ID NO.1 as described in the example section.
In one embodiment, the first nucleotide sequence of the double stranded RNA
according to the invention are fully complementary with SEQ ID NO.1. This means that there
are no mismatches between the first RNA sequence and SEQ ID NO.1 over the entire length
of either the first RNA sequence or SEQ ID NO.1, whichever is the shortest. Preferably, the
first nucleotide sequence and SEQ ID NO.1 are fully complementary, comprising only G-C
and A-U base pairs. Preferably, the first RNA sequence is selected from the group consisting
of SEQ ID NOs 3-7, which are fully complementary with SEQ ID NO.1. Most preferably the
first RNA sequence is SEQ ID NO. 5. When the first nucleotide sequence is 21 nucleotides or
less (SEQ ID NOs. 3, 4 and 5) all nucleotides of the first nucleotide sequence base pair with
SEQ ID NO.1. When the first nucleotide sequence is longer than 21 nucleotides (SEQ ID
NOs. 6 and 7), all nucleotides of SEQ ID NO.1 base pair with the first nucleotide sequence.
The additional nucleotides that are comprised in the first RNA sequence do not base pair with
SEQ ID NO.1. When the first nucleotide sequence is longer than 21 nucleotides and the
additional nucleotides are to be part of the guide strand, preferably the additional nucleotides
are complementary to the sequence flanking sequence of SEQ ID NO.1 as present in SEQ ID
NO.2.
With regard to the second RNA sequence, the second RNA sequence is substantially
complementary with the first RNA sequence. The second RNA sequence combined with the
first RNA sequence forms a double stranded RNA. As said, this is to form a suitable substrate
for the RNA interference machinery such that a guide sequence derived from the first RNA
sequence is comprised in the RISC complex in order to sequence specifically inhibit
18023480_1 (GHMatters) P43075NZ00
expression of its target, i.e. Huntingtin gene expression. As said, such double stranded RNA
is preferably comprised in a pre-miRNA scaffold, a pri-miRNA scaffold, a shRNA, or an
siRNA.
The sequence of the second RNA sequence has similarities with the target sequence.
However, the substantial complementarity with the first RNA sequence may be selected to
have less substantial complementarity as compared with the substantial complementarity
between the first RNA sequence and SEQ ID NO.1. Hence, the second RNA sequence may
comprise 0, 1, 2, 3, 4, or more mismatches, 0, 1, 2, 3, or more G-U wobble base pairs, and
may comprise insertions of 0, 1, 2, 3, 4, nucleotides and/or deletions of 0, 1, 2, 3, 4,
nucleotides. Preferably the first RNA sequence and the second RNA sequence are
substantially complementary, said complementarity comprising 0, 1, 2 or 3 G-U base pairs
and/or wherein said complementarity comprises at least 17 base pairs.
These mismatches, G-U wobble base pairs, insertions and deletions, are with regard
to the first RNA sequence, i.e. the double stranded region that is formed between the first and
second RNA sequence. As long as the first and second RNA sequence can substantially
base pair, and are capable of inducing sequence specific inhibition of SEQ ID NO.1, such
substantial complementarity is allowed according to the invention. It is also understood that
substantially complementarity between the first RNA sequence and the second RNA
sequence may depend on the double stranded RNA design of choice. It may depend for
example on the miRNA scaffold that is chosen for in which the double stranded RNA is to be
incorporated.
SEQ ID Second RNA sequence length
8 5’-UCGAGUCCCUCAAGUCCUU-3’ 19
9 5’-UUCGAGUCCCUCAAGUCCUU-3’ 20
5’-CUUCGAGUCCCUCAAGUCCUU-3’ 21
11 5’-CCUUCGAGUCCCUCAAGUCCUU-3’ 22
12 5’-GCCUUCGAGUCCCUCAAGUCCUU-3’ 23
13 5’-CUUCGAGUCUCAAGUCCUU-3’ 19
14 5’-ACGAGUCCCUCAAGUCCUC-3’ 19
Table 2. Second RNA sequences.
In one embodiment, a second RNA sequence is selected from the group consisting of
SEQ ID NOs. 8-14. In Table 2, examples of said second RNA sequences in accordance with
18023480_1 (GHMatters) P43075NZ00
the invention are listed. SEQ ID NOs. 8, 9, 10, 11 and 12 are fully complementary with SEQ
ID NO.1 over their entire length. SEQ ID NOs. 13 and 14 can be combined with a first
nucleotide having a sequence corresponding to SEQ ID NO.5 of 21 nucleotides, which is
complementary with SEQ ID NO.1 over its entire length. SEQ ID NO.13 is complementary
with SEQ ID NO.5 having a two nucleotide deletion (resulting in the corresponding 2
nucleotides of SEQ ID NO.5 not base paired) and 19 nucleotides base paired. SEQ ID NO.14
is complementary with SEQ ID NO.5 having a two nucleotides deletion, two mismatches, and
17 nucleotides base paired. The complementarity can also be seen in figure 2B, as the
combination of SEQ ID NO.5 and SEQ ID NO.13 is present in miH12_155, and the
combination of SEQ ID NO.5 and SEQ ID NO.14 is present in miH12_451a. Hence, as is
clear from the above, the second RNA sequence does not require complementarity with the
first RNA sequence, but may comprise deletions, insertions and mutations that result in
mismatches, as compared with SEQ ID NO.1.
As is clear from the above, the substantial complementarity between the first RNA
sequence and the second RNA sequence, may comprise mismatches, deletions and/or
insertions relative to a first and second RNA sequence being fully complementary (i.e. fully
base paired). In one embodiment, the first and second RNA sequences have at least 11
consecutive base pairs. Hence, at least 11 consecutive nucleotides of the first RNA sequence
and at least 11 consecutive nucleotides of the second RNA sequence are fully
complementary. In another embodiment the first and second RNA sequence have at least 15
nucleotides that base pair. Said base pairing between at least 15 nucleotides of the first RNA
sequence and at least 15 nucleotides of the second RNA sequence may consist of G-U, G-C
and A-U base pairs, or may consist of G-C and A-U base pairs. In still another embodiment,
the first and second RNA sequence have at least 15 nucleotides that base pair and have at
least 11 consecutive base pairs. In still another embodiment, the first RNA sequence and the
second RNA sequence are substantially complementary, wherein said complementarity
comprises at least 17 base pairs. Said 17 base pairs may preferably be 17 consecutive base
pairs, said base pairing consisting of G-U, G-C and A-U base pairs or consisting of G-C and
A-U base pairs.
In one embodiment, the first and second nucleotide sequence are selected from the
group of SEQ ID NOs. 3 and 8; 4 and 9; 5 and 10; 5 and 13; 5 and 14; 6 and 11; and 7 and
12. These combinations of first and second nucleotide sequences were shown to be effective
when comprised in siRNAs or miRNA scaffolds.
The first and second nucleotide sequences that are substantially complementary
preferably do not form a double stranded RNA of 30 consecutive base pairs or longer, as
these can trigger an innate immune response via the double-stranded RNA (dsRNA)-
18023480_1 (GHMatters) P43075NZ00
activated protein kinase pathway. Hence, the double stranded RNA is preferably less than 30
consecutive base pairs. Preferably, a pre-miRNA scaffold, a pri-miRNA scaffold, a shRNA, or
an siRNA comprising the double stranded RNA according to the invention does not comprise
consecutive base pairs.
Preferably the double stranded RNA according to the invention is comprised in a pre-
miRNA or pri-miRNA scaffold. A pri-miRNA scaffold comprises a pre-miRNA scaffold. The
pre-miRNA scaffold comprises the double stranded RNA of the invention, i.e. the first RNA
sequence and the second RNA sequence. Preferably, the double stranded DNA according to
the invention is comprised in a pri-miRNA scaffold derived from miR-451a (also referred to as
miR-451) or miR-155. Examples of double stranded RNAs according to the invention
comprised in a pre-miRNA scaffold are depicted in Fig.2A. The sequence of these pre-
miRNAs are listed in table 3 below.
SEQ ID NO. Name Sequence
pre- 5’-CUUGGGAAUGGCAAGGAAGGACUUGAGGGACUCG
miR451a AAGACGAGUCCCUCAAGUCCUCUCUUGCUAUACCCAGA-3’
16 pre-miR155 5’-UGCUGAAGGACUUGAGGGACUCGAAGGUUUUGGCCA
CUGACUGACCUUCGAGUCUCAAGUCCUUCAGGA-3’
Table 3. Pre-miRNA scaffolds with SEQ ID NO.5
The pre-mRNA sequence of SEQ ID NO.15 consists of a 5' arm corresponding to nucleotides
1-16 of SEQ ID NO.15, a first RNA sequence corresponding to SEQ ID NO.5 from
nucleotides 17-37 of SEQ ID NO.15, a second RNA sequence corresponding to SEQ ID
NO.14 from nucleotides 38-56 of SEQ ID NO.15, and a 3’-arm corresponding to nucleotides
57-72 of SEQ ID NO.15. The pre-miR451a scaffold according to the invention comprises the
’-arm corresponding to nucleotides 1-16 of SEQ ID NO.15, followed by the first nucleotide
sequence according to the invention, the second nucleotide sequence according to the
invention, and the 3’-arm corresponding to nucleotides 57-72 of SEQ ID NO.15. Preferably,
the first and second RNA sequences are selected such that when comprised in the pri-
miR451a scaffold a predicted structure highly similar or as shown in Fig.2B is obtained.
Preferably the base pairs that are formed between the first and second RNA sequence are G-
C, G-U and A-U base pairs and preferably the sequence length of the first RNA sequence is
21 nucleotides and the length of the second RNA sequence is preferably 19 nucleotides.
Preferably the base pairs that are formed between the first and second RNA sequence are G-
18023480_1 (GHMatters) P43075NZ00
C and A-U base pairs and preferably the sequence length of the first RNA sequence is 21
nucleotides and the length of the second RNA sequence is preferably 19 nucleotides. Without
being bound by theory, this pri-R451a scaffold may be preferred as it does not result in a
passenger strand to be processed by the RNAi machinery to be incorporated into RISC
(Cheloufi et al.,2010 Jun 3;465(7298):584-9). From an siRNA or miRNA duplex, in principle
both strands can be incorporated into RISC. As the passenger strand (corresponding to the
second sequence) may result in targeting of transcripts other than a huntingtin transcript,
using the pri-miR451a or pre-miR451a scaffold may allow one to avoid such unwanted
targeting. When tested for potential “passenger strand” activity, no activity was detected with
a pri-451a scaffold (see figures 4A and 4B). The processing of the pre-miRNA hairpin is
understood to be Dicer independent and to be cleaved by Ago2 (Yang et al., Proc Natl Acad
Sci U S A. 2010 Aug 24;107(34):15163-8).
The pre-mRNA sequence of SEQ ID NO.16 consists of a 5' arm corresponding to
nucleotides 1-5 of SEQ ID NO.16, a first RNA sequence corresponding to SEQ ID NO.5 from
nucleotides 6-26 of SEQ ID NO.16, a loop sequence from nucleotides 27-45 of SEQ ID
NO.16, a second RNA sequence corresponding to SEQ ID NO.13 from nucleotides 46-64 of
SEQ ID NO.16, and a 3’-arm corresponding to nucleotides 65-69 of SEQ ID NO.16. The pre-
155 scaffold comprising the first and second RNA sequence according to the invention
comprises the 5’-arm corresponding to nucleotides nucleotides 1-5 of SEQ ID NO.16, the first
RNA sequence, a loop sequence corresponding to nucleotides 27-45 of SEQ ID NO.16, the
second RNA sequence, and a 3’-arm corresponding to nucleotides 65-69 of SEQ ID NO.16.
Preferably, the first and second RNA sequence are selected such that when comprised in the
pre-miR155 scaffold (or pri-miRNA scaffold) a predicted structure highly similar as shown in
Fig.2B is obtained. Preferably the base pairs that are formed between the first and second
RNA sequence are G-C or A-U base pairs and preferably the sequence length of the first
RNA sequence is 21 nucleotides and the length of the second RNA sequence is preferably
19 nucleotides. Said 19 nucleotides are preferably fully complementary with nucleotides 2-18
of a first nucleotide sequence of 21 nucleotides in length.
A pre-miRNA sequence when comprised in a larger RNA sequence requires 5’- and
3’- single stranded flanking sequences that allow Drosha recognition and cleavage. Said
sequences that are suitable to allow for Drosha recognition and cleavage are 5’-pri-miRNA
sequence and the 3’-pri-miRNA sequence. For example, the expressed pre-miH12_155
sequence as depicted in figure 5A is flanked by 5’-pri-miRNA and the 3’-pri-miRNA
sequences of miR155 in the expression vector CMV-miH12-155 (Fig.2C). The pri-miRNA
sequence comprising the miRH12_155 is listed in Fig. 2F, the 5’-pri-miRNA corresponding to
nucleotides 1-87 and the 3’-pri-miRNA corresponding to 147-272. Likewise, the CAG-miH12-
18023480_1 (GHMatters) P43075NZ00
451 and PGK-miH12-451 pri-miRNA sequences that are expressed by their respective
vectors in figures 2D and 2E are shown in figures 2G and 2H. The 5’-pri-miRNA and the 3’-
pri-miRNA of the expressed CAG-miH12-451 RNA corresponding to nucleotides 1-302 and
375-605, and the 5’-pri-miRNA and the 3’-pri-miRNA of the expressed of PGK-miH12-451
RNA corresponding respectively to nucleotides 1-516 and 589-819. The length of the single-
stranded flanks can vary but is typically around 80 nt (Zeng and Cullen, J Biol Chem. 2005 Jul
29;280(30):27595-603; Cullen, Mol Cell. 2004 Dec 22;16(6):861-5) The minimal length of the
single-stranded flanks can easily be determined as when it becomes too short, Drosha
processing may fail and sequence specific inhibition will be reduced or even absent. In one
embodiment, the pri-miRNA scaffold carrying the first and second RNA sequence according
to the invention has a 5’-sequence flank and a 3’ sequence flank relative to the predicted re-
miRNA structure of at least 50 nucleotides. The pre-miRNA and the pri-miRNA derived
sequences are preferably all derived from the same naturally occurring pri-miRNA sequence.
The pre-miRNA sequence of SEQ ID NO.15 and SEQ ID NO.16 are encoded by the
DNA sequences as depicted in figures 2C (SEQ ID NO.16), 2D (SEQ ID NO.15), and 2E
(SEQ ID NO.15). Pri-miRNA sequences comprising said pre-miRNA sequences are depicted
in figures 2F (SEQ ID NO.16), G (SEQ ID NO.15) and H (SEQ ID NO.15). The pri-miRNA
encoded by CMV-miH12-155 correspond to nucleotides 1433-1704 of Fig.2C, of CAG-miH12-
451 to nucleotides 1716-2320 of Fig. 2D and of PGK-miH12-451 to nucleotides 278-1097 of
Fig. 2E. Likewise, the first and second RNA sequences are to be incorporated as described
above for the pre-miRNAs.
The double stranded RNAs according to the invention, incorporated in an siRNA,
shRNA, pri-mRNA scaffold or pre-miRNA scaffold can be provided in a cell using methods
known in the art, such as lipofection, transfection or using any other suitable means therefor.
The double stranded RNAs according to the invention may be synthetic double stranded
RNAs or natural double stranded RNAs. Synthetic double stranded RNAs and may comprise
nucleic acids containing known analogs of natural nucleotides. The said double stranded
RNA has similar properties as compared to their natural counterparts and an RNA
interference activity similar to or improved over double stranded RNAs that consist entirely of
non-synthetic double stranded RNA. For example, synthetic siRNAs may include in their
design the use of Locked Nucleic Acid (a ribose ring connected by a methylene bridge
(orange) between the 2’-O and 4’-C atoms), modified nucleotides such as nucleotides
comprising phosphorothioates, 2′-O-Me, 2′-O-allyl and 2′-deoxy-fluorouridine. It is well known
that double stranded RNAs, e.g. siRNAs, can accommodate quite a number of modifications
at both base-paired and non-base-paired positions without significant loss of activity.
18023480_1 (GHMatters) P43075NZ00
Preferably, the double stranded RNA of the invention is a double stranded RNA that consists
of natural nucleotides, such as obtained from expression of a double stranded RNA from.
Hence, in one embodiment, the said double stranded RNAs of the invention are
encoded by a DNA sequence. The said DNA sequence encoding the said double stranded
RNA, e.g. as comprised in an siRNA, shRNA, pri-mRNA scaffold or pre-miRNA scaffold, is
comprised in an expression cassette. It is understood that when the double stranded RNA is
to be e.g. an siRNA, consisting of two RNA strands, that there are two expression cassettes
required. One encoding an RNA strand comprising the first RNA sequence, the other cassette
encoding an RNA strand comprising the first RNA strand. When the double stranded RNA is
comprised in a single RNA molecule, e.g. encoding a shRNA, pre-miRNA or pri-miRNA, one
expression cassette may suffice. A pol II expression cassette may comprise a promoter
sequence a sequence encoding the RNA to be expressed followed by a polyadenylation
sequence. In case the double stranded RNA that is expressed comprises a pri-miRNA
scaffold, the encoded RNA sequence may encode for intron sequences and exon sequences
and 3’-UTR’s and 3’-UTRs. A pol III expression cassette in general comprises a promoter
sequence, followed by the DNA sequence encoding the RNA (e.g. shRNA sequence, pre-
miRNA, or a strand of the double stranded RNAs to be comprised in e.g. an siRNA or
extended siRNA). A pol I expression cassette may comprise a pol I promoter, followed by the
RNA encoding sequence and a 3’- Box. Expression cassettes for double stranded RNAs are
well known in the art, and any type of expression cassette can suffice, e.g. one may use a pol
III promoter, a pol II promoter or a pol I promoter (i.a. ter Brake et al., Mol Ther. 2008
Mar;16(3):557-64, Maczuga et al., BMC Biotechnol. 2012 Jul 24;12:42). Examples of
expression cassettes expressing a double stranded RNA according to the invention are
depicted in figures 2C-E.
Preferably a pol II promoter is used, such as the PGK promoter, a CBA promoter or a
CMV promoter (see figures 2C-D). As Huntington’s disease affects neurons, it may in
particulary be useful to use a neurospecific promoter. Examples of suitable neurospecific
promoters are Neuron-Specific Enolase (NSE), human synapsin 1, caMK kinase and tubuline.
Other suitable promoters that can be contemplated are inducible promoters, i.e. a promoter
that initiates transcription only when the host cell is exposed to some particular stimulus.
Said expression cassettes according to the invention can be transferred to a cell,
using e.g. transfection methods. Any suitable means may suffice to transfer an expression
cassette according to the invention. Preferably, gene therapy vectors are used that stably
transfer the expression cassette to the cells such that stable expression of the double
stranded RNAs that induce sequence specific inhibition of the huntingtin gene as described
above can be achieved. Suitable vectors may be lentiviral vectors, retrotransposon based
18023480_1 (GHMatters) P43075NZ00
vector systems, or AAV vectors. It is understood that as e.g. lentiviral vectors carry an RNA
genome, the RNA genome will encode for the said expression cassette such that after
transduction of a cell, the said DNA sequence and said expression cassette is formed.
Preferably a viral vector is used such as AAV. Preferably the AAV vector that is used is an
AAV vector of serotype 5. AAV of serotype 5 may be in particularly useful for transducing
neurons as shown in the examples. The production of AAV vectors comprising any
expression cassette of interest is well described in ; WO2007/046703, WO2007/148971,
WO2009/014445, WO2009/104964, WO2011/122950, WO2013/036118, which are
incorporated herein in its entirety.
AAV sequences that may be used in the present invention for the production of AAV
vectors, e.g. produced in insect or mammalian cell lines, can be derived from the genome of
any AAV serotype. Generally, the AAV serotypes have genomic sequences of significant
homology at the amino acid and the nucleic acid levels, provide an identical set of genetic
functions, produce virions which are essentially physically and functionally equivalent, and
replicate and assemble by practically identical mechanisms. For the genomic sequence of the
various AAV serotypes and an overview of the genomic similarities see e.g. GenBank
Accession number U89790; GenBank Accession number J01901; GenBank Accession
number AF043303; GenBank Accession number AF085716; Chlorini et al. (1997, J. Vir. 71:
6823-33); Srivastava et al. (1983, J. Vir. 45:555-64); Chlorini et al. (1999, J. Vir. 73:1309-
1319); Rutledge et al. (1998, J. Vir. 72:309-319); and Wu et al. (2000, J. Vir. 74: 8635-47).
AAV serotypes 1, 2, 3, 4 and 5 are preferred source of AAV nucleotide sequences for use in
the context of the present invention. Preferably the AAV ITR sequences for use in the context
of the present invention are derived from AAV1, AAV2, and/or AAV5. Likewise, the Rep52,
Rep40, Rep78 and/or Rep68 coding sequences are preferably derived from AAV1, AAV2 and
AAV5. The sequences coding for the VP1, VP2, and VP3 capsid proteins for use in the
context of the present invention may however be taken from any of the known 42 serotypes,
more preferably from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 or AAV9 or
newly developed AAV-like particles obtained by e.g. capsid shuffling techniques and AAV
capsid libraries.
In another embodiment, a host cell is provided comprising the said DNA sequence, or
said expression cassette according to the invention. For example, the said expression
cassette or DNA sequence may be comprised in a plasmid contained in bacteria. Said
expression cassette or DNA sequence may also be comprised in a production cell that
produces e.g. a viral vector.
As shown in the example section, and as explained above, the double stranded RNA
according to the invention, the DNA sequence according to invention, the expression cassette
18023480_1 (GHMatters) P43075NZ00
according to the invention and the gene therapy vector according to the invention are for use
in a medical treatment, in particular for use in the treatment of Huntington’s disease. Said
medical treatment when using an AAV vector (or likewise for a gene therapy vector)
comprising a direct infusion of AAV vector of the invention into the brain. Said direct infusion
in further embodiments comprising an intrathecal infusion of the vector into the cerebrospinal
fluid. Such an intrathecal infusion represents an efficient way to deliver the gene therapy
vector to the CNS and to target the neurons. Preferably striatal and cortical structures are
targeted via intrastriatal convection enhanced diffusion (CED) delivery of AAV vectors through
injections into the striatum. More preferably, for a larger coverage of the CNS, injections are
into the striatum and into the thalamus as well. Hence, AAV vectors are delivered
intrastriatally, or delivered intrastriatally and intrathalamically through convection enhanced
diffusion (CED) injections in the striatum, or the striatum and the thalamamus. Such injections
are preferably carried out through MRI-guided injections. Said methods of treatments are in
particular useful for human subjects having Huntington’s disease. It is understood that the
treatment of Huntington’s disease involves human subjects having Huntington’s disease
including human subjects having a genetic predisposition of developing Huntington’s disease
that do not yet show signs of the disease. Hence, the treatment of human subjects with
Huntington’s disease includes the treatment of any human subject carrying an Huntingtin
allele with more than 35 CAG repeats.
Embodiments
1. A double stranded RNA comprising a first RNA sequence and a second RNA sequence
wherein the first and second RNA sequence are substantially complementary, wherein the
first RNA sequence has a sequence length of at least 19 nucleotides and is substantially
complementarity to SEQ ID NO. 1.
2. A double stranded RNA according to embodiment 1, wherein said double stranded RNA
is capable of reducing huntingtin gene expression.
3. A double stranded RNA according to embodiment 1 or embodiment 2, wherein the
double stranded RNA is comprised in a pre-miRNA scaffold, a pri-miRNA scaffold, a shRNA,
or an siRNA, preferably a pre-miRNA scaffold.
18023480_1 (GHMatters) P43075NZ00
4. A double stranded RNA according to any one of embodiments 1-3, wherein the first
RNA sequence has a sequence length of at least 20 nucleotides, preferably of at least 21
nucleotides.
5. A double stranded RNA according to any one of embodiments 1-4, wherein the first
RNA sequence is fully complementary to SEQ ID. NO.1.
6. A double stranded RNA according to any one of embodiments 1-5 wherein the first
strand is selected from the group consisting of SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5,
SEQ ID NO.6, and SEQ ID NO.7.
7. A double stranded RNA according to any one of embodiments 1-6, wherein the first
strand and second strand are selected from the group consisting of the combinations of
SEQ ID NO. 3 and 8; SEQ ID NO. 4 and 9; SEQ ID NO. 5 and 10; SEQ ID NO. 5 and 13;
SEQ ID NO. 5 and 14; SEQ ID NO. 6 and 11; and SEQ ID NO. and 7 and 12.
8. A double stranded RNA according to any one of embodiments 1-7, wherein the double
stranded RNA is comprised in a pre-miRNA scaffold derived from miR-451a or miR-155.
9. A DNA sequence encoding the double stranded RNA according to any one of
embodiments 1-8.
. An expression cassette encoding a double stranded RNA in accordance with any one of
embodiments 1-9.
11. An expression cassette according to embodiment 10, wherein the expression cassette
comprises the PGK promoter, a CMV promoter, a neurospecific promoter or a CBA promoter.
12. A gene therapy vector comprising the expression cassette according to embodiment 10
or 11.
13. A gene therapy vector according to embodiment 12, wherein the gene therapy vector is
an AAV vector, preferably an AAV vector of serotype 5.
14. A host cell comprising the DNA sequence according to embodiment 9 or the expression
cassette according to embodiment 10 or embodiment 11.
18023480_1 (GHMatters) P43075NZ00
. A double stranded RNA according to any one of embodiments 1-8, a DNA sequence
according to embodiment 9, an expression cassette according to embodiment 10 or
embodiment 11, a gene therapy vector according to embodiment 12 or embodiment 13, for
use in a medical treatment.
16. A double stranded RNA according to any one of embodiments 1-8, a DNA sequence
according to embodiment 9, an expression cassette according to embodiment 10 or
embodiment 11, a gene therapy vector according to embodiment 12 or embodiment 13, for
use in the treatment of Huntington’s disease.
Examples
miRNA scaffold expression constructs & siRNAs
To create miRNA scaffold vectors based on miR155, 21 nucleotide (bp) sequences
fully complementary with the selected target sequences in HTT as indicated in Fig.1, were
embedded into the pri-mir-155 backbone of pcDNA6.2-GW/EmGFP-miR (Invitrogen,
Carlsbad, CA) resulting in pVD-CMV-miHTT-155 (an example of an expression cassette
sequence is depicted in Fig. 2C, the pre-miRNA and pri-miRNA sequence as comprised in
the expressed RNA are depicted in figure 2B and 2F, respectively). The pri-mir-155
constructs were designed based on the instructions provided by Invitrogen (BLOCK-iT, Pol II
miR RNAi expression Vector Kits, Verson E, June 22, 2007, 25-0857) by annealing synthetic
double-stranded oligonucleotides in the BsaI site of pcDNA6.2-GW/emGFP-mir155. The
structure of all artificial pre-miRNA as encoded by the miHtt constructs was verified using the
Mfold software (Nucleic Acids Res. 31 (13), 3406-15, (2003), using mfold version 3.5, as
available online on http://mfold.rna.albany.edu/?q=mfold). The predicted structure of the pre-
miRNA-155 scaffold carrying the sequence corresponding with SEQ ID NO.5 is shown in
figure 2B. The DNA sequence encoding the expression construct for the pri-miRNA-155
scaffold with SEQ ID NO.5 as a selected first sequence is listed in figure 2C (SEQ ID NO.
17), this construct is also referred to as miH12 and its target H12. For the other 20 selected
target sequences, the sequences were designed to be fully complementary with the target
sequences as depicted in Fig.1, and the miRNA scaffold having the same structural features
as depicted in Fig. 2B, i.e. the second RNA sequence embedded in the scaffold corresponds
to the sequence to which the first RNA sequence selected is fully complementary, but having
a 2 nucleotide deletion in the center. As a control similarly, a scrambled RNA sequence was
used as a first RNA sequence, and like above, a second RNA sequence was designed to
18023480_1 (GHMatters) P43075NZ00
create a vector pVD-CMV-miScr-155. The constructs contained GFP for allowing both miRNA
expression and transduction visualization in vitro and in vivo.
A miRNA scaffold vector based on miR451a was created. The DNA sequence
encoding the pri-miR-451 scaffold was synthesized based on the predicted mature mir-451
sequence being replaced by the H12 targeting sequence, i.e. SEQ ID NO.5 as first RNA
sequence. The second RNA sequence was designed to be fully complementary to
nucleotides 2-18 of the first RNA sequence. The second RNA sequence was selected such
that the predicted RNA structure of the artificial pre-miRNA sequence adopted a similar
structure as the original wild-type structure. The structure of the pre-miRNA as encoded by
the constructs was verified using the Mfold software (Nucleic Acids Res. 31 (13), 3406-15,
(2003), using mfold version 3.5, as available online on http://mfold.rna.albany.edu/?q=mfold).
The predicted structure using SEQ ID NO.5 is shown in Fig.2B. Two different miR451a
scaffolds expressing vectors were made. The DNA sequences of the expression constructs
are depicted in figures 2D and 2E, the corresponding respective pri-miRNA scaffold
sequences as comprised in the expressed RNA are listed in figures 2G and 2H. Figure 2D
shows the DNA sequence of the expression cassette of pVD-CAG-miH12-451, which
expresses the miRNA scaffold with a CAG promoter, and in figure 2E the DNA sequence of
the expression cassette of pVD-PGK-miH12-451 is shown, which uses a PGK promoter.
Synthetic siRNA targeting HTT at the miH12 target, i.e. SEQ ID NO.1, were designed
with lengths of 19-23 bp (Table 1). The siRNAs comprised first and second nucleotide
sequence corresponding to SEQ ID NOs. 3 and 8; 4 and 9; 5 and 10; 6 and 11; and 7 and 12.
The siRNAs were designed to have 3’-UU overhangs in both strands.
Reporter constructs
The psiCheck-2 constructs LucHTT containing the complete HTT exon 1 sequence
was designed and cloned following the instructions as provided by Promega (siCHECK™
Vectors, C8011, Promega Benelux b.v., Leiden, The Netherlands). LucHTT comprises SEQ
ID NO.1 and flanking sequences thereof as present in SEQ ID NO.2 (see Fig.1B). The
LucH12_451a reporter comprises the sequence complementary to the second RNA
sequence as designed to be expressed by pVD-CAG-miH12-451 and pVD-PGK-miH12-451.
All constructs have been sequenced, and the correct sequence has been verified. The
knockdown efficacy of all miRNA scaffolds and siRNAs were determined on specific
luciferase reporters in vitro. Hek293T cells were co-transfected with the miHtt and the
Luciferase reporter in a 1:1 ratio (miR-155, PGK-miH12-451), or 1:10 ratio (CAG-miH12-451,
i.e. the CAG promoter is very strong). Renilla luciferase knockdown was measured 48 h post
18023480_1 (GHMatters) P43075NZ00
transfection (p.t.), and Firefly was measured as an internal control. miScr was used as a
negative control and was set at 100%.
In vitro results
Among the miH1-miH21 constructs targeting exon 1, miH12 induced the strongest
Luciferase reporter knockdown with a 75-80% reduction (Figure 3A). siRNAs targeting H12,
i.e. SEQ ID NO.1, were all shown to have similar knockdown efficiency, showing upon an
increase in dose a stronger knockdown. SiRNAs of 19 and 21 base pairs showed some more
inhibition as compared to the other siRNAs tested. Next generation sequencing (NGS)
analysis of the RNA expressed from pVD-CMV-miHTT-155 was performed and showed a
preference in guide and passenger strands (see e.g. fig. 2B (7)) corresponding to the first
RNA and second RNA sequence as designed to be part of the miRNA scaffold. The pVD-
CAG-miH12-451 and pVD-PGK-miH12-451 were tested for targeting both LucHTT and
LucH12_451a. Both the CAG and PGK constructs showed sequence specific inhibition
(Fig.4A), whereas a Luc reporter was comprising a sequence fully complementary to the
second RNA sequence of the constructs was not reduced.
In vivo knockdown using AAV vectors in mice
The expression construct CMV-miH12-155 from pVD-CMV-miHTT-155 was cloned in
an AAV5 vector backbone and AAV5 produced using the baculovirus production system. As a
control CMV-miScr-155 was also incorporated in an AAV5 backbone to serve as a negative
control. For monitoring the brain transduction efficiency, the expression cassettes contained
GFP (Figure 5A). An AAV-5 vector carrying a luciferase reporter construct, Luc73QHTT,
comprising the target sequence SEQ ID NO.1 (i.e. the complete HTT exon 1 sequence with
73 CAG repeats) and flanking sequences thereof as present in SEQ ID NO.2 (see Fig.1B).
Balb/6 mice (N5) were co-injected intrastriatally with 2 μl of AAV5-Luc73QHtt/SNP (3.6x10
13 13
gc/ml), and AAV5-miScr (1.8x10 gc/ml) or AAV5-miH12 (1.8x10 gc/ml) in a 1:5 ratio. A
separate group was injected with AAV5-Luc73QHtt/SNP and PBS. Luciferase expression was
monitored at 2, 4, and 6 p.i. by MS.). Already at 1 week p.i., there was a clear knockdown of
Luc19QHtt/wt by miH12 compared to miScr and Luc19QHtt/wt-only animals (Figure 7b and
c). A trend was shown indicating a significant decrease in Luciferase reporter expression in
time, being almost undetectable (miH12 #1 and #2) in the brain compared with the control
groups indicating a strong knockdown of the HTT target by CMV-miH12-155. At the end of
the experiment, the Luc73QHtt/SNP fluorescence in the CMV-miH12-155 group was about 1
log lower compared to miScr.
18023480_1 (GHMatters) P43075NZ00
In vivo knockdown using AAV vectors in an HD animal models
AAV5-CMV-miH12-155 was tested in the LV82Q HD rat model (Drouet et al.
2009, Ann Neurol. 2009 Mar;65(3):276-85). The model is based on the striatal
overexpression of the first 171 amino acids of the HTT mutant fragment with 82 CAG repeats
linked to a fragment of exon 67 containing the SNP C/T. HD rats were injected with AAV5-
CMV-miH12-155 or a control AAV5-CMV-miScr-155 (Figure 6A). Rats were injected
intrastriatally with LV82Q and one week later with AAV5-CMV-miH12-155 or AAV5-
CMV-miScr-155. The neuro-protective effect of AAV5-CMV-miH12-155 was determined
based on histological staining (DARP32, EM48, GFP and Iba1) of HD rat brain sections at the
early and late time points (Figures 6B, 6C and 6D, 2 weeks p.i.). DARP32 lesions (Fig. 6B,
upper panel) indicate neurodegeneration and can be observed as white spots on the brain
sections. The panel clearly shows less neuronal death and hence no white spots in the brain
sections of AAV5-CMV-miH12-155 rats. Brain sections were stained for mutant HTT
aggregates (EM48, Figure 6B) seen as small brown dots on the slides. There was clearly less
neurodegeneration and less mutant HTT aggregates in HD rats injected with AAV5-CMV-
miH12-155 as compared to the control group (Figure 6B, middle and lowest panels). Similar
results were obtained at the late time point of 8 weeks post-injection (data not shown). GFP
histology (brown staining) results indicated efficient striatal transduction with all vectors used
in the current study (Figure 6C). Additionally, almost no immune response was detected at 8
weeks p.i. based on Iba1 staining (Figure 6D).
AAV5-CMV-miH12-155 was subsequently further tested in the humanized Hu97/18
HD mouse model (Southwell et al. 2013, Hum Mol Genet. 2013 Jan 1;22(1):18-34). This
model has the murine Hdh gene replaced by two copies of the human HTT, one carrying 97
CAG repeats and the other 18. Detailed characterization of the motor, psychiatric, cognitive,
electrophysiological, neuropathological and biochemical changes in the Hu97/18 mouse
model as a result of disease progression has been performed. AAV5-CMV-miH12-155 was
injected in 2-months old humanized Hu97/18 HD mouse model by delivery via intracerebral
delivery via convection-enhanced diffusion (IC-CED) in the striatum or slow (IC-slow delivery)
in the striatum or intracerebroventricular delivery (ICV) in the ventricles of the brain. GFP
fluorescence indicated complete transduction of the mouse striatum upon slow and CED
delivery (Figure 7A). Western blot analysis of the human HTT showed knockdown by AAV5-
CMV-miH12-155 in the striatum when the CED delivery was applied (Figure 7B).
Comparison H12 with prior art target sequences
Target sequences from prior art in the proximity of the H12 sequence were compared
with the H12 sequences. siRNAs and miRNA scaffolds were constructed and a direct
18023480_1 (GHMatters) P43075NZ00
comparison was carried out using the Luciferase reporter system as described above. Low
concentrations of siRNAs were transfected (0.25 nM) in triplicates in order to avoid off-target
effects skewing the results. The siRNAs were made with fully complementary guide and
passenger strands (G-C and A-U base pairs) and having a UU-3’ overhang in both strands. A
scrambled siRNA was used as a control and values were measured relative to control. The
H12 siRNA showed strongest inhibition (see figure 8A). Likewise, miRNA scaffolds were
made based on miR-155 as described above in accordance with the instructions of Invitrogen
and a direct comparison was made as well. The R6.1 and R6.2 scaffolds were made by
replacing 19 and 18 nucleotides that are perfectly complementary to R6.1 and R6.2 target
sequences into the guide sequence of the engineered miR-155 scaffold from Invitrogen.
Therefore, depending on the pre-miRNA processing by Dicer, the processed R6 guide strand
may contain nucleotides from miR-155 scaffold at the end(s) of the sequence. miRNA
scaffolds were transfected as described above using different ratios between miRNA
construct and reporter (miRNA scaffold construct: Luciferase reporter). A scrambled miRNA
construct was used as a control and values were measured relative to control. Figure 8B
shows a 1:1 ratio, whereas figure 8C shows a 1:10 ratio. The H12 miRNA scaffold showed
strongest inhibition. H12 showed pronounced strong inhibition for both siRNAs and miRNAs,
in particular at low concentrations which may be considered most relevant for in vivo
application.
Target Target sequence SI. L. Id.
’-CUUCGAGUCCCUCAAGUCCUU-3’
H12 34 21 21
’-GAAGGCCUUCGAGUCCCUCAA-3’
H11 33 21 15
’-GGCCUCGAGUCCCUCAAGUCC-3’
R1 (siHUNT-2) 46 21 18
’-GGCCUUCGAGUCCCUCAAGUC----3’
R2 (shD2) 47 21 18
’-AGGCCUUCGAGUCCCUCAAGU-3’
R3 48 21 17
(siRNA-DExon1)
’-AUGAAGGCCUUCGAGUCCCUC-3’
R4 (HDAS 07) 49 21 13
’-GCCUUCGAGUCCCUCAAGU-3’
R6.1 (54) 50 19 17
’-CCUUCGAGUCCCUCAAGU-3’
R6.2 (55) 51 18 17
Table 4. Targets from prior art compared with H12. The target sequences are shown.
The target nucleotides that have identity with the H12 target sequence are underlined. (SI.
indicates SEQ ID NO.; L. indicates the nucleotide length, Id. Indicates the number of
nucleotides that have identity with H12). (R1 is derived from the siRNA siHUNT-2 from
18023480_1 (GHMatters) P43075NZ00
Rodriguez-Lebron et al., 2005, Mol Ther. Vol 12 No.4: 618-633, R2 is derived from an
expressed shRNA shD2 from Franich et al., 2008, Mol Ther, Vol. 16 No.5; 947-956), R3 is
derived from the siRNA-DExon1 from US20080015158, R4 is derived from HDAS 07
WO2008134646, R6.1 and R6.2 are derived from a list of about 1750 hypothetical siRNAs
designed to target the huntingtin gene (WO2005105995).
18023480_1 (GHMatters) P43075NZ00
Claims (20)
1. CLAIMS 5 1. A double stranded RNA comprising a first RNA sequence and a second RNA sequence wherein the first and second RNA sequence are substantially complementary, wherein the first RNA sequence has a sequence length of at least 19 nucleotides and is complementary to SEQ ID NO. 1, wherein the first sequence is selected from the group consisting of SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.7, 10 and wherein said double stranded RNA is capable of reducing huntingtin gene expression.
2. A double stranded RNA according to claim 1, wherein the double stranded RNA is comprised in a pre-miRNA scaffold, a pri-miRNA scaffold, a shRNA, or an siRNA. 15
3. A double stranded RNA according to claim 1 or claim 2, wherein the double stranded RNA is comprised in a pre-miRNA scaffold.
4. A double stranded RNA according to any one of claims 1-3, wherein the first RNA sequence has a sequence length of at least 20 nucleotides.
5. A double stranded RNA according to any one of claims 1 -4, wherein the first RNA sequence has a sequence length of at least 21 nucleotides.
6. A double stranded RNA according to any one of claims 1-5, wherein the first RNA 25 sequence is fully complementary to SEQ ID. NO.1.
7. A double stranded RNA according to any one of claims 1-6, wherein the first sequence and second sequence are selected from the group consisting of the combinations of SEQ ID NO. 3 and 8; SEQ ID NO. 4 and 9; SEQ ID NO. 5 and 10; SEQ ID NO. 5 and 13; SEQ ID NO. 30 5 and 14; SEQ ID NO. 6 and 11; and SEQ ID NO. and 7 and 12.
8. A double stranded RNA according to any one of claims 1-7, wherein the double stranded RNA is comprised in a pre-miRNA scaffold from miR-451a or miR-155. 35
9. A DNA sequence encoding a double stranded RNA according to any one of claims 1- 18023480_1 (GHMatters) P43075NZ00
10. An expression cassette encoding a double stranded RNA according to any one of claims 1-8. 5
11. An expression cassette according to claim 10, wherein the expression cassette comprises the PGK promoter, a CMV promoter, a neurospecific promoter or a CBA promoter.
12. A gene therapy vector comprising an expression cassette according to claim 10 or 11. 10
13. A gene therapy vector according to claim 12, wherein the gene therapy vector is an AAV vector.
14. A gene therapy vector according to claim 13, wherein the gene therapy vector is an AAV vector of serotype 5.
15. An isolated or non-human host cell comprising a DNA sequence according to claim 9 or an expression cassette according to claim 10 or 11.
16. Use of a double stranded RNA according to any one of claims 1-8, a DNA sequence 20 according to claim 9, an expression cassette according to claim 10 or 11, or a gene therapy vector according to any one of claims 12-14 in the manufacture of a medicament for treating Huntington’s disease in a subject or a subject genetically predisposed for Huntington’s disease who does not yet show symptoms of Huntington’s disease. 25
17. The use according to claim 16, wherein the vector is to be administered by direct infusion of the vector into the brain.
18. The use according to claim 16, wherein the vector is to be administered by intrathecal infusion of the vector into the cerebrospinal fluid.
19. The use according to claim 16, wherein the vector is an AAV vector that is to be delivered intrastriatally, or intrastriatally and intrathalamically through convection enhanced diffusion injections in the striatum, or in the striatum and the thalamamus. 35
20. The use according to claim 19, wherein the AAV vector is to be delivered through MRI-guided injections. 18023480_1 (GHMatters) P43075NZ00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14200308.6 | 2014-12-24 | ||
EP14200308 | 2014-12-24 | ||
PCT/EP2015/081157 WO2016102664A1 (en) | 2014-12-24 | 2015-12-23 | Rnai induced huntingtin gene suppression |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ733296A NZ733296A (en) | 2021-10-29 |
NZ733296B2 true NZ733296B2 (en) | 2022-02-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11371044B2 (en) | RNAi induced huntingtin gene suppression | |
EP3146051B1 (en) | Huntington's disease therapeutic compounds | |
US20210330813A1 (en) | Rnai induced c9orf72 suppression for the treatment of als/ftd | |
CA2688514A1 (en) | Rna interference suppression of neurodegenerative diseases and methods of use thereof | |
US20220010314A1 (en) | Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3 | |
NZ733296B2 (en) | Rnai induced huntingtin gene suppression | |
WO2023198745A1 (en) | Nucleic acid regulation of apoe | |
WO2023031370A1 (en) | Microrna system | |
WO2023198663A1 (en) | Nucleic acid regulation of snca | |
WO2023198702A1 (en) | Nucleic acid regulation of c9orf72 | |
WO2023198662A1 (en) | Novel systems for nucleic acid regulation |